Abvc Biopharma Net Profit Margin Growth & History (ABVC)
Abvc Biopharma's net profit margin was −2,671.81% for fiscal 2025.
View full Abvc Biopharma company overviewAbvc Biopharma annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2,671.81% | — |
| 2023 | 2023-12-31 | −5,109.26% | −3415.77 pp |
| 2022 | 2022-12-31 | −1,693.50% | +1914.97 pp |
| 2021 | 2021-12-31 | −3,608.47% | −1415.38 pp |
| 2020 | 2020-12-31 | −2,193.08% | −1632.57 pp |
| 2019 | 2019-12-31 | −560.51% | +86623.64 pp |
| 2018 | 2018-12-31 | −87,184.16% | — |
| 2015 · Sep 30 | 2015-09-30 | −960.74% | — |
| 2013 | 2013-09-30 | −2,906.79% | +15811.78 pp |
| 2012 | 2012-09-30 | −18,718.57% | +19483.66 pp |
| 2011 | 2011-09-30 | −38,202.23% | −25409.09 pp |
| 2010 | 2010-09-30 | −12,793.14% | — |
Abvc Biopharma quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −256.61% | −155.20 pp |
| Q3 2024 | 2024-09-30 | −101.41% | +20784.49 pp |
| Q2 2024 | 2024-06-30 | −804.44% | +36247.63 pp |
| Q1 2024 | 2024-03-31 | −235,203.24% | −233781.50 pp |
| Q4 2023 | 2023-12-31 | −17,705.68% | −16879.88 pp |
| Q3 2023 | 2023-09-30 | −20,885.90% | −12120.93 pp |
| Q2 2023 | 2023-06-30 | −37,052.07% | −36457.88 pp |
| Q1 2023 | 2023-03-31 | −1,421.74% | +21943.19 pp |
| Q4 2022 | 2022-12-31 | −825.80% | — |
| Q3 2022 | 2022-09-30 | −8,764.97% | −6940.21 pp |
| Q2 2022 | 2022-06-30 | −594.19% | +5676.49 pp |
| Q1 2022 | 2022-03-31 | −23,364.93% | −22910.69 pp |
| Q3 2021 | 2021-09-30 | −1,824.75% | +19.53 pp |
| Q2 2021 | 2021-06-30 | −6,270.68% | −5306.48 pp |
| Q1 2021 | 2021-03-31 | −454.24% | +1207.56 pp |
| Q4 2020 | 2020-12-31 | −7,989.86% | −6873.65 pp |
| Q3 2020 | 2020-09-30 | −1,844.29% | −1171.82 pp |
| Q2 2020 | 2020-06-30 | −964.21% | −643.82 pp |
| Q1 2020 | 2020-03-31 | −1,661.80% | −1250.32 pp |
| Q4 2019 | 2019-12-31 | −1,116.21% | — |
| Q3 2019 | 2019-09-30 | −672.46% | +91335.57 pp |
| Q2 2019 | 2019-06-30 | −320.39% | +22474.28 pp |
| Q1 2019 | 2019-03-31 | −411.47% | — |
| Q3 2018 | 2018-09-30 | −92,008.03% | — |
| Q2 2018 | 2018-06-30 | −22,794.67% | −22552.59 pp |
| Q3 2017 | 2017-06-30 | −242.09% | — |
| Q1 2017 | 2016-12-31 | −300.48% | — |
| Q4 2015 | 2015-09-30 | −28,691.09% | — |
| Q2 2015 | 2015-03-31 | 49.51% | — |
| Q2 2013 | 2013-03-31 | −13,702.50% | −4348.06 pp |
| Q1 2013 | 2012-12-31 | −2,189.05% | +11336.52 pp |
| Q2 2012 | 2012-03-31 | −9,354.43% | −76400.82 pp |
| Q1 2012 | 2011-12-31 | −13,525.57% | +3637.95 pp |
| Q2 2011 | 2011-03-31 | 67,046.39% | — |
| Q1 2011 | 2010-12-31 | −17,163.52% | — |
| Q3 2010 | 2010-06-30 | −7,398.83% | — |
Abvc Biopharma net profit margin trends
Over the last five fiscal years, Abvc Biopharma's net profit margin decreased from −2,193.08% to −2,671.81%, a change of −478.72 percentage points. The latest reported quarter, Q3 2025, shows −256.61%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abvc Biopharma source filings ↗